Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response

Clinical and Experimental Immunology

Volumn 139, Issue 3, 2005, Pages 498-505

  Farajnia, S ^a,b   Mahboudi, F ^b   Ajdari, S ^b   Reiner, N E ^c   Kariminia, A ^b   Alimohammadian, Mohammad Hossein ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amastigote class I nuclease; CD8+ T cells; IFN ; LmaCIN Leishmania major

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5; LEISHMANIA MAJOR AMASTIGOTE CLASS 1 NUCLEASE; LEISHMANIA VACCINE; MICROBIAL ENZYME; NUCLEASE; RECOMBINANT ENZYME; RECOMBINANT LEISHMANIA MAJOR AMASTIGOTE CLASS 1 NUCLEASE; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIA PIFANOI; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SKIN LEISHMANIASIS; SUPERNATANT; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANALYSIS OF VARIANCE; ANTIGENS, PROTOZOAN; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-5; LEISHMANIASIS, CUTANEOUS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PROTOZOAN VACCINES; TH1 CELLS; VACCINES, SYNTHETIC;

EID: 14744291199     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02702.x     Document Type: Article

References (51)

1. World Health Organization 2001. WHO information by topics or disease. Available at: http://www.who.int/emc/disease/leish/ index.html.
2. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19:502-8.
3. Locksley RM, Louis JA. Immunology of leishmaniasis. Curr Opin Immunol 1992; 4:413-18.
4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2:845-58.
5. Locksley RM, Scott P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol Today 1991; 12:A58-61.
6. Satoskar A, Bluethmann H, Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995; 63:4894-9.
7. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61:2952-9.
8. Handman E, Button LL, McMaster RW. Leishmania major, production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 1990; 70:427-35.
9. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56:3272-9.
10. Skeiky YA, Guderian JA, Benson DR et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cell to express a Th1 type cytokine profile and to produce interleukin-12. J Exp Med 1995; 81:1527-37.
11. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63:4261-7.
12. Webb JR, Kaufmann D, Campos-Neto A, Reed SG. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 1996; 157:5034-41.
13. Webb JR, Campos-Neto A, Ovendale PJ et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66:3279-89.
14. Farajnia S, Alimohammadian MH, Reiner NE, Karimi M, Ajdari S, Mahboudi F. Molecular characterization of a novel amastigote specific class I nuclease from Leishmania major amastigotes. Int J Parasitol 2004; 34:899-908.
15. Kar S, Soong L, Colmenares M, Goldsmith-Pestana K, McMahon-Pratt D. The immunologically protective P-4 antigen of Leishmania amastigotes. A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. J Biol Chem 2000; 275:37789-97.
16. Neubert TA, Gottlieb M. An indudble 3́-nucleotidase/nuclease from the trypanosomatid Crithidia luciliae. Purification and characterization. J Biol Chem 1990; 265:7236-42.
17. Campbell TA, Zlotnick GW, Neubert TA, Sacci JB Jr, Gottlieb M. Purification and characterization of the 3́-nucleotidase/nuclease from promastigotes of Leishmania donovani. Mol Biochem Parasitol 1991; 47:109-17.
18. Gbenle GO, Dwyer DM. Purification and properties of 3́-nucleotidase of Leishmania donovani. Biochem J 1992; 285:41-6.
19. Debrabant A, Gottlieb M, Dwyer DM. Isolation and characterization of the gene encoding the surface membrane 3́-nucleotidase/ nuclease of Leishmania donovani. Mol Biochem Parasitol 1995; 71:51-63.
20. Debrabant A, Ghedin E, Dwyer DM. Dissection of the functional domains of the Leishmania surface membrane 3-nucleotidase/ nuclease, a unique member of the class I nuclease family. J Biol Chem 2000; 275:16366-72.
21. Sopwith WF, Debrabant A, Yamage M, Dwyer DM, Bates PA. Developmentally regulated expression of a cell surface class I nuclease in Leishmania mexicana. Int J Parasitol 2002; 32:449-59.
22. Soong L, Duboise SM, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63:3559-66.
23. Campbell K, Diao H, Ji J, Soong L. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect Immun 2003; 71:6270-8.
24. Alimohammadian MH, Kivanjah M, Pak F, Gaznavi A, Kharazmi A. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. Trans R Soc Trop Med Hyg 1993; 87:550-1.
25. Alimohammadian MH, Khamesipour A, Darabi H et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 2002; 21:174-80.
26. Maasho K, Satti I, Nylen S, Guzman G, Koning F, Akuffo HA. Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors. J Infect Dis 2000; 182:570-8.
27. Akuffo H, Maasho K, Howe R. Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells. Clin Exp Immunol 1993; 94:516-21.
28. Alvarado R, Enk C, Jaber K, Schnur L, Frankenburg S. Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in a group of children in Jericho. Trans R Soc Trop Med Hyg 1989; 83:189-92.
29. Kemp M, Hey AS, Kurtzhals JAL et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994; 96:410-15.
30. Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13:1009-17.
31. Haberer JE, Da-Cruz AM, Soong L et al. Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infect Immun 1998; 66:3100-5.
32. Coutinho SG, Oliveira MP, Da-Cruz AM et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 1996; 84:144-55.
33. Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, Akuffo H. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol 2001; 124:255-61.
34. Maasho K, McMahon-Pratt D, Raita J, Raud M, Britton S, Soong L, Akuffo H. Evaluation of amastigote reactive cells in human cutaneous leishmaniasis caused by Leishmania aethiopica. Clin Exp Immunol 2003; 132:316-22.
35. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998; 4:1409-15.
36. + T cells. J Immunol 2000; 165:915-24.
37. Mendez S, Gurunathan S, Kamhawi S. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001; 166:5122-8.
38. + T cells. Infect Immun 1993; 61:3730-8.
39. + T cells following secondary infection of mice immune to Leishmania major. Infect Immun 1994; 62:2575-81.
40. + cytotoxic T cell responses. Eur J Immunol 1994; 24:2813-7.
41. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168:3992-4000.
42. + T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun 2003; 71:3172-82.
43. Da-Cruz AM, Bittar R, Mattos M et al. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol 2002; 9:251-6.
44. Holaday BJ, Pompeu MM, Jeronimo S et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 1993; 92:2626-32.
45. Ghalib HW, Piuvezam MR, Skeiky YA et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92:324-9.
46. Bacellar O, D'Oliveira A Jr, Jeronimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000; 12:1228-31.
47. Chatelain R, Mauze S, Coffman RL. Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol 1999; 21:211-18.
48. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correia Costa JM, Verwaerde C. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 2002; 51:367-79.
49. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166:1141-7.
50. Belkaid Y, Hoffmann K, Mendez S et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potencial of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2002; 194:1497-506.
51. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.